Translate page

× To share and enhance best practice management of CML, experts and interested clinicians can discuss difficult or interesting CML cases here. Clinicians submit a brief history of the patient and the case for discussion (no more than 200 words) by posting it in this forum ("+ NEW TOPIC" button below). Please include the country of origin.

Each clinical case will be forwarded to the expert clinical panel for a brief independent response. Consideration should be given to patient confidentiality. Details that are not critical to the case can be changed to preserve anonymity. Please consider including your email with the case. This will not be posted on the website, but is useful should further details be requested by the moderator.

As a full clinical history is necessary for accurate comment, cases and comments on the Forum are ONLY ACCEPTED FROM CLINICIANS. If individual patients have a specific question we encourage them to contact their healthcare provider. General questions can be emailed to info@cml-foundation.org.

DISCLAIMER: The iCMLf does not recommend or endorse any specific tests, physicians, products, procedures, or opinions, and disclaims any representation, warranty, or guaranty as to the same. Reliance on any information provided in this Forum is solely at your own risk.

ponatinib dose for pediatric patients

  • manuel abecasis
  • manuel abecasis's Avatar Topic Author
6 years 1 month ago #1144 by manuel abecasis
ponatinib dose for pediatric patients was created by manuel abecasis
A 6 y o boy with Ph+ ALL relapsed with a T315I mutation. Does anyone know the adequate ponatinib dosage for this patient?
  • Meinolf Suttorp
  • Meinolf Suttorp's Avatar Topic Author
6 years 1 month ago #1147 by Meinolf Suttorp
Replied by Meinolf Suttorp on topic ponatinib dose for pediatric patients
Dear Dr. Abecasis,

You ask for the dose of Ponatinib in a 6-year old child.
Assuming that the body surface of an adult is on average 1.73 sqm, the starting dose for a child would be 25 mg/sqm. However, I'm not aware of a formal trial having tried to collect data on any dosage in children with T315 I mutation. So this approach would be a compassionate use in your responsibility as treating physician as the safety and efficacy of Ponatinib (Iclusig, TM) in patients less than 18 years of age have not been established.

Ponatinib is indicated for adult patients with chronic, accelerated, or blast phase T315I-positive chronic myeloid leukemia (CML) for whom no other TKI therapy is indicated. Note: Not indicated and is not recommended for the treatment of patients with newly diagnosed chronic phase CML.

The optimal dose in adults is not identified. In adults the dose is 45 mg PO qDay initially; continue as long as there is no evidence of disease progression or unacceptable toxicity. Coadministration with strong CYP3A inhibitors: Reduce dose to 30 mg qDay in adults. In clinical trials on adult patients , the starting dose was 45 mg PO once daily; however, 59% of the adult patients required dose reductions to 30 mg or 15 mg once daily. Consider reducing the dose in patients who have achieved a major cytogenetic response.
Consider discontinuing if response has not occurred by 3 months.

Also it might be prudent to ask for further information from the supplier:
ARIAD Pharmaceuticals, Inc; 26 Landsdowne Street; Cambridge, MA 02339-4234

With kind regards and all the best wishes for the child Meinolf Suttorp
  • Nobuko Hijiya
  • Nobuko Hijiya's Avatar Topic Author
6 years 1 month ago #1148 by Nobuko Hijiya
Replied by Nobuko Hijiya on topic ponatinib dose for pediatric patients
Meinolf is right about no data in pediatrics. Phase 1 in pediatric population has not been done yet. There is only one case report in the literature about pediatric experience (Pediatr Blood Cancer. 2015 Nov;62(11):2050-1). They used 45 mg daily for an adolescent >70kg but reduced it to 15 mg for a concern of side effects.

We have used it for a 9 yo with Ph+ ALL and T315I mutation. This weight is about 30 kg and 1 m2 BSA. The patient received 15 mg daily and had a great response. I also hear from my US colleagues about their experience with children.

Nobuko Hijiya
Moderators: Melissa Davis-Bishop